Pointing towards the global market! Novo Nordisk A/S Sponsored ADR Class B (NVO.US) expands Ireland factory in an attempt to seize market share with the oral version of Wegovy.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) plans to increase its investment in Ireland to produce the oral version of its popular weight loss drug Wegovy for markets outside the United States. The CEO of Novo Nordisk A/S Sponsored ADR Class B, Mike Doustdar, stated that the company will expand its production facility in Athlone, central Ireland. However, he refused to disclose the size of the investment. Doustdar mentioned that the oral version of Wegovy was launched in early January and has become one of the most successful drug launches in history, with over 240,000 American patients currently using it. Novo Nordisk A/S Sponsored ADR Class B currently produces and supplies the oral version of the weight loss drug for the U.S. market. Despite the intensifying price war in the weight loss drug market, Novo Nordisk A/S Sponsored ADR Class B hopes that this oral medication will become a key weapon in regaining its dominance in the weight loss market and closing the gap with competitors like Eli Lilly (LLY.US). Doustdar said, "If we were ready to give up, we wouldn't be investing in building a factory in Ireland." Ireland is one of the global centers for pharmaceutical manufacturing. Eli Lilly produces the active ingredients of its flagship weight loss and diabetes drugs locally. Additionally, the country's economy heavily relies on U.S. investment and is also a focal point of President Trump's tariff threats.